Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation.

Kovarik JJ, Kaltenecker CC, Kopecky C, Domenig O, Antlanger M, Werzowa J, Eskandary F, Kain R, Poglitsch M, Schmaldienst S, Böhmig GA, Säemann MD.

Sci Rep. 2019 Jul 5;9(1):9762. doi: 10.1038/s41598-019-46114-x.

2.

Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus.

Kopecky C, Lytvyn Y, Domenig O, Antlanger M, Kovarik JJ, Kaltenecker CC, Poglitsch M, Perkins BA, Rye KA, Cherney DZI, Säemann MD.

Diabetologia. 2019 Jun;62(6):1090-1093. doi: 10.1007/s00125-019-4871-8. Epub 2019 Apr 11. No abstract available.

PMID:
30976852
3.

A randomized controlled trial-based algorithm for insulin-pump therapy in hyperglycemic patients early after kidney transplantation.

Werzowa JM, Säemann MD, Mohl A, Bergmann M, Kaltenecker CC, Brozek W, Thomas A, Haidinger M, Antlanger M, Kovarik JJ, Kopecky C, Song PXK, Budde K, Pascual J, Hecking M.

PLoS One. 2018 Mar 8;13(3):e0193569. doi: 10.1371/journal.pone.0193569. eCollection 2018.

4.

A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.

Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, Hidalgo LG, Haslacher H, Kaltenecker CC, Aretin MB, Oberbauer R, Posch M, Staudenherz A, Handisurya A, Reeve J, Halloran PF, Böhmig GA.

J Am Soc Nephrol. 2018 Feb;29(2):591-605. doi: 10.1681/ASN.2017070818. Epub 2017 Dec 14.

5.

Molecular remodeling of the renin-angiotensin system after kidney transplantation.

Antlanger M, Domenig O, Kovarik JJ, Kaltenecker CC, Kopecky C, Poglitsch M, Säemann MD.

J Renin Angiotensin Aldosterone Syst. 2017 Apr-Jun;18(2):1470320317705232. doi: 10.1177/1470320317705232.

6.

Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease.

Antlanger M, Bernhofer S, Kovarik JJ, Kopecky C, Kaltenecker CC, Domenig O, Poglitsch M, Säemann MD.

Ann Med. 2017 Sep;49(6):525-533. doi: 10.1080/07853890.2017.1313447. Epub 2017 Apr 17.

PMID:
28358246
7.

Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients.

Kovarik JJ, Kopecky C, Antlanger M, Domenig O, Kaltenecker CC, Werzowa J, Hecking M, Mahr S, Grömmer M, Wallner C, Aumayr K, Kain R, Zuckermann A, Poglitsch M, Säemann MD.

J Heart Lung Transplant. 2017 Mar;36(3):355-365. doi: 10.1016/j.healun.2016.08.022. Epub 2016 Sep 13.

PMID:
27773450
8.

Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney.

Domenig O, Manzel A, Grobe N, Königshausen E, Kaltenecker CC, Kovarik JJ, Stegbauer J, Gurley SB, van Oyen D, Antlanger M, Bader M, Motta-Santos D, Santos RA, Elased KM, Säemann MD, Linker RA, Poglitsch M.

Sci Rep. 2016 Sep 21;6:33678. doi: 10.1038/srep33678.

9.

HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients.

Kopecky C, Ebtehaj S, Genser B, Drechsler C, Krane V, Antlanger M, Kovarik JJ, Kaltenecker CC, Parvizi M, Wanner C, Weichhart T, Säemann MD, Tietge UJ.

J Am Soc Nephrol. 2017 Mar;28(3):769-775. doi: 10.1681/ASN.2016030262. Epub 2016 Sep 9.

10.

Molecular regulation of the renin-angiotensin system in haemodialysis patients.

Kovarik JJ, Antlanger M, Domenig O, Kaltenecker CC, Hecking M, Haidinger M, Werzowa J, Kopecky C, Säemann MD.

Nephrol Dial Transplant. 2016 May;31(5):851. doi: 10.1093/ndt/gfw071. Epub 2016 Mar 23. No abstract available.

PMID:
27190396
11.

Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study.

Eskandary F, Bond G, Kozakowski N, Regele H, Marinova L, Wahrmann M, Kikić Ž, Haslacher H, Rasoul-Rockenschaub S, Kaltenecker CC, König F, Hidalgo LG, Oberbauer R, Halloran PF, Böhmig GA.

Transplantation. 2017 Mar;101(3):631-641. doi: 10.1097/TP.0000000000001195.

PMID:
27120452
12.

Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.

Kopecky C, Genser B, Drechsler C, Krane V, Kaltenecker CC, Hengstschläger M, März W, Wanner C, Säemann MD, Weichhart T.

Clin J Am Soc Nephrol. 2015 Feb 6;10(2):224-31. doi: 10.2215/CJN.06560714. Epub 2014 Nov 25.

13.

Molecular regulation of the renin-angiotensin system in haemodialysis patients.

Kovarik JJ, Antlanger M, Domenig O, Kaltenecker CC, Hecking M, Haidinger M, Werzowa J, Kopecky C, Säemann MD.

Nephrol Dial Transplant. 2015 Jan;30(1):115-23. doi: 10.1093/ndt/gfu265. Epub 2014 Aug 8. Erratum in: Nephrol Dial Transplant. 2016 May;31(5):851.

PMID:
25107336
14.

Restoration of renal function does not correct impairment of uremic HDL properties.

Kopecky C, Haidinger M, Birner-Grünberger R, Darnhofer B, Kaltenecker CC, Marsche G, Holzer M, Weichhart T, Antlanger M, Kovarik JJ, Werzowa J, Hecking M, Säemann MD.

J Am Soc Nephrol. 2015 Mar;26(3):565-75. doi: 10.1681/ASN.2013111219. Epub 2014 Jul 28.

15.

p38α senses environmental stress to control innate immune responses via mechanistic target of rapamycin.

Katholnig K, Kaltenecker CC, Hayakawa H, Rosner M, Lassnig C, Zlabinger GJ, Gaestel M, Müller M, Hengstschläger M, Hörl WH, Park JM, Säemann MD, Weichhart T.

J Immunol. 2013 Feb 15;190(4):1519-27. doi: 10.4049/jimmunol.1202683. Epub 2013 Jan 11.

Supplemental Content

Loading ...
Support Center